GlassScriptPhysician profile
Marti R Gibbs
NPI 1083694905
$9,880.79
in general payments reported to CMS, 2019-2025
56 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $1,255 · 2021: $1,746 · 2022: $1,715 · 2023: $1,800 · 2024: $1,123 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,864 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,863.84 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,236.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $809.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $757.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $638.80 | 2019-2025 | |
| Pfizer INC. | $554.21 | 2019-2025 | |
| Amarin Pharma, INC. | $510.92 | 2019-2021 | |
| Lilly USA, LLC | $476.40 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $475.41 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $386.14 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $361.86 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $324.10 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $292.58 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.58 | 2019-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $226.76 | 2021-2025 | Rexulti |
| Tris Pharma INC | $213.66 | 2022-2025 | Dyanavel Xr |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $213.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $179.97 | 2019-2025 | Spravato |
| Abbott Laboratories | $177.04 | 2019-2025 | Freestyle Libre 3 |
| Eisai INC. | $176.11 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $172.89 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $127.45 | 2021-2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $98.81 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $95.03 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $89.95 | 2019-2023 | Jornay Pm |
| Medtronic, INC. | $87.14 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Esperion Therapeutics, INC. | $66.76 | 2021-2022 | |
| Exact Sciences Corporation | $64.93 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $63.96 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $54.78 | 2022 | |
| Allergan, INC. | $50.94 | 2019-2020 | |
| Corcept Therapeutics | $50.83 | 2024-2025 | Korlym |
| Upsher-Smith Laboratories LLC | $50.43 | 2020-2021 | |
| Mannkind Corporation | $45.02 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.87 | 2022 | |
| Gilead Sciences, INC. | $34.53 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $29.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.38 | 2021 | |
| Adlon Therapeutics L.P. | $26.53 | 2020-2021 | |
| Beta Bionics, INC. | $23.13 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Daiichi Sankyo INC. | $21.90 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $21.40 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.25 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $20.52 | 2024 | Fanapt |
| Ionis Pharmaceuticals, INC. | $19.54 | 2025 | Tryngolza |
| Endo Pharmaceuticals INC. | $18.10 | 2019 | |
| Bausch Health US, LLC | $16.73 | 2022 | |
| Currax Pharmaceuticals LLC | $16.15 | 2025 | Contrave |
| Axsome Therapeutics, INC. | $16.03 | 2025 | Auvelity |
| Cequr Corporation | $15.19 | 2024 | Cequr Simplicity |
| Lundbeck LLC | $14.91 | 2025 | Rexulti |
| Aytu Biopharma, INC. | $14.09 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.68 | 2024 | Caplyta |
| Corium, LLC | $13.11 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.02 | 2023 | Quviviq |
| Genentech USA, INC. | $13.00 | 2019 | |
| Strongbridge US INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marti Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.